The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms are actively being developed and will be launched soon.
Characterization of multifocal breast cancer using the 70-gene signature in clinical low-risk patients – A sub-analysis of the EORTC 10041/BIG 03-04 MINDACT trial